Iterative Health has raised a total of $180 million across multiple funding rounds, with its largest being a $150 million Series B round in January 2022. The Cambridge, Massachusetts-based company is pioneering AI-driven precision medicine in gastroenterology, focusing on optimizing clinical trials for inflammatory bowel disease (IBD) and enhancing colorectal cancer screening. Iterative Health’s technology leverages machine learning and computer vision to analyze endoscopic images and clinical data, helping clinicians standardize disease severity characterization and predict therapeutic response.
Keep reading to explore Iterative Health’s funding journey, key investors, and what’s next for this innovative healthcare company.
What Is Iterative Health and What Does It Do?
Founded by Jonathan Ng, Iterative Health is headquartered in Cambridge, Massachusetts, with additional locations in New York City. The company specializes in AI-based precision medicine for gastroenterology, focusing on optimizing clinical trials for IBD. Its platform, including tools like SKOUT, interprets endoscopic images and clinical data to provide standardized assessments and improve patient outcomes in colorectal cancer screening and surveillance.
With a team of 51–200 employees, Iterative Health is advancing AI solutions to enhance disease characterization, predict therapeutic responses, and support clinical decision-making for gastroenterology professionals.
How Much Funding Has Iterative Health Raised?
- Series A
- Amount Raised: $30M
- Date: August 2021
- Motivation: To support the development of AI-driven precision medicine technologies for gastroenterology.
- Series B
- Amount Raised: $150M
- Date: January 2022
- Lead Investors: Insight Partners, Clearlake Capital Group
- Motivation: To advance AI-driven precision medicine for gastroenterology, improve patient outcomes, and accelerate clinical trials for IBD and colorectal cancer.
Total Funding Raised: $180M
Current Valuation: ~$500M (estimated)
Latest Funding Date: January 1, 2022
Key Investors
- Insight Partners
- Details: Global venture capital and private equity firm founded in 1995, investing in high-growth technology and software companies.
- Investment Focus Areas: High-growth technology, software, ScaleUp companies
- Notable Investments: Twitter, Shopify, DocuSign
- Clearlake Capital Group
- Details: Private equity firm founded in 2006, managing over $60 billion in assets.
- Investment Focus Areas: Technology, industrials, consumer sectors
- Notable Investments: Ivanti, Diligent, ConvergeOne
- Obvious Ventures
- Details: VC firm focused on companies with positive environmental and social impact, founded in 2014.
- Investment Focus Areas: Sustainable systems, healthy living
- Notable Investments: Beyond Meat, Medium, Olly
- Johnson & Johnson Innovation - JJDC Inc.
- Details: Venture arm of Johnson & Johnson, investing in healthcare and life sciences innovations.
- Investment Focus Areas: Pharmaceuticals, medical devices, consumer health
- Notable Investments: Auris Health, Grail, HeartFlow
- Eli Lilly
- Details: Global pharmaceutical company founded in 1876, focusing on innovative medicines.
- Investment Focus Areas: Oncology, diabetes, immunology
- Notable Investments: Loxo Oncology, Prevail Therapeutics, Dermira
Where Is Iterative Health’s Headquarters?
Iterative Health is headquartered in Cambridge, Massachusetts, providing access to top AI talent, clinical partners, and healthcare institutions. Its location enables collaboration with leading hospitals, research centers, and biotech companies to advance AI-driven solutions in gastroenterology.
What’s Next for Iterative Health?
Iterative Health is poised to revolutionize gastroenterology through AI-powered tools, including automated polyp detection and endoscopic scoring systems. These innovations aim to standardize insights from endoscopic videos and optimize clinical trials, enhancing patient care and clinical decision-making.
Future fundraising opportunities are promising, supported by high-profile investors like Insight Partners and Clearlake Capital. Challenges include regulatory approvals, scaling technical operations, and integrating AI solutions into clinical workflows. With growing adoption of precision medicine and AI in healthcare, Iterative Health is set for continued growth, innovation, and impact.
Get Investor & Funding Insights with TexAu
TexAu provides detailed fundraising information on companies like Iterative Health. Track investors, monitor funding rounds, and gather actionable insights to strengthen your sales and business strategy.
Sign up for free on TexAu and turn data into smarter, faster business decisions.
